Retatrutide Cuts Blood Sugar and Weight in Landmark T2D Trial — Published in The Lancet

A single weekly injection just dropped HbA1c by nearly two full percentage points and melted away more than 15 percent of body weight in people with type 2 diabetes. That is not a marketing claim. That is what happened in a 537-person, randomized, placebo-controlled trial published in The Lancet on June 13, 2026.

Retatrutide—Eli Lilly’s triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously—just delivered its strongest clinical data to date. And the data raises a question the diabetes world has been dancing around for two years: do we even need metformin as a first-line drug anymore?

The trial that landed in The Lancet

The study is called TRANSCEND-T2D-1. It is a 40-week, phase 3, randomized, double-blind, placebo-controlled trial conducted across 48 clinical sites in the United States, Mexico, and India. Eli Lilly sponsored and funded the trial, which is registered as NCT06354660 on ClinicalTrials.gov.

Researchers enrolled 537 adults with type 2 diabetes inadequately controlled by diet and exercise alone. That detail matters. These were people who had not yet been placed on any diabetes medication. Their average HbA1c at baseline was 7.9 percent, their average BMI was 35.8 kg/m², and the mean duration of diabetes was only 2.5 years. This is the early-stage, treatment-naive population that the diabetes field increasingly wants to target before complications develop.

Participants were randomly assigned in a 1:1:1:1 ratio to receive retatrutide at 4 mg, 9 mg, or 12 mg, or a placebo, all administered as once-weekly subcutaneous injections. The primary endpoint was the change in HbA1c from baseline to week 40. A key secondary endpoint was percentage change in body weight.

The numbers that matter

The results were unambiguous. For the treatment regimen estimand (which measures the effect of the drug as actually taken):

HbA1c reduction: Retatrutide 4 mg: −1.69% | 9 mg: −1.86% | 12 mg: −1.94% versus −0.81% for placebo. The estimated treatment differences versus placebo were −0.88%, −1.04%, and −1.12% respectively (all p<0.0001).

Body weight reduction: Retatrutide 4 mg: −11.5% | 9 mg: −13.9% | 12 mg: −15.3% versus −2.6% for placebo. That means the highest dose group lost roughly six times as much weight as the placebo group over 40 weeks.

For context, a person with a starting weight of 220 pounds in the 12 mg group would have lost approximately 34 pounds in under a year. On placebo, the same person would have lost about 6 pounds.

Why this trial is different

Lilly has already published retatrutide data from the TRIUMPH program, which focuses on obesity. That data showed dramatic weight loss and generated headlines about people dropping out of trials because they were losing too much weight. TRANSCEND-T2D-1 is different in several ways that matter for the broader peptide and diabetes conversation.

It tested retatrutide as monotherapy. Most diabetes trials add a new drug on top of metformin or other standard therapies. This trial asked a more fundamental question: can retatrutide alone, without any background medication, bring blood sugar under control in newly diagnosed or early-stage type 2 diabetes? The answer is yes, decisively.

The population was treatment-naive. These participants had never taken a diabetes drug. Their average disease duration was 2.5 years. This is the exact population that clinicians are increasingly trying to reach—people early enough in the disease process that aggressive intervention could change the trajectory of their condition.

The Lancet published it. The Lancet is one of the highest-impact medical journals in the world. Publication here signals that the editorial and peer-review process found the methodology rigorous and the results clinically significant. This is not a conference abstract or a press release.

What about safety?

No drug this effective comes without trade-offs. The most frequent adverse events were gastrointestinal—nausea, diarrhea, constipation, and vomiting—which is consistent with the entire GLP-1 agonist class. These events were generally mild to moderate and subsided over time.

Discontinuation rates due to adverse events were 2 to 5 percent in the retatrutide groups versus 0 percent in the placebo group. No severe hypoglycemia was reported, which is notable given that retatrutide improves insulin secretion. Two deaths occurred during the study, both in the 4 mg group, and both were determined to be unrelated to the study drug.

The safety profile is consistent with what we have seen from other GLP-1 agonists. The glucagon receptor component, which distinguishes retatrutide from tirzepatide, did not produce problematic blood sugar spikes—likely because the GLP-1 and GIP activation counterbalance the glucose-raising potential of glucagon at these doses.

Where retatrutide fits in the treatment landscape

The current standard of care for type 2 diabetes starts with metformin, then escalates to GLP-1 agonists, SGLT2 inhibitors, or insulin as needed. Retatrutide’s TRANSCEND data challenges that algorithm. If a single weekly injection can reduce HbA1c by nearly 2 percent and produce 15 percent weight loss without any background therapy, the argument for starting with metformin—a drug that typically reduces HbA1c by 1 to 1.5 percent and produces minimal weight loss—gets weaker.

This does not mean metformin is obsolete. It is cheap, well-understood, and has decades of safety data. But for patients who can access and afford a triple agonist, the efficacy gap is substantial.

The trial also adds to a growing body of evidence that the GLP-1/GIP/glucagon triple-agonist class represents a genuine step forward, not just an incremental improvement. Retatrutide’s weight loss numbers in T2D (15.3 percent) exceed what tirzepatide typically produces in similar populations, and the HbA1c reductions are among the highest ever seen in a phase 3 diabetes monotherapy trial.

The Oria take

TRANSCEND-T2D-1 is the kind of trial that shifts the conversation. It moves retatrutide from “promising obesity drug” to “potential new standard of care for type 2 diabetes.” The Lancet publication gives it the credibility stamp that matters for clinicians, payers, and regulators.

For the peptide community, the key takeaway is mechanistic. Retatrutide’s triple-agonist approach—hitting GLP-1, GIP, and glucagon receptors in a single molecule—produces results that neither single nor dual agonists can match. The glucagon receptor activation, which initially seemed counterintuitive for a metabolic drug, is proving to be the differentiator that drives both fat oxidation and the magnitude of weight loss.

Lilly has not yet announced an FDA submission date for the T2D indication, but the data is now strong enough that submission in late 2026 or early 2027 seems likely. If approved, retatrutide would be the first triple-agonist peptide therapy available for both obesity and type 2 diabetes.

We will be watching the TRANSCEND program closely. Additional trials, including TRANSCEND-CKD for chronic kidney disease, are underway. The triple-agonist era is no longer theoretical.

Evidence Grade: A — Phase 3 randomized controlled trial, published in The Lancet, 537 participants, 48 sites, double-blind and placebo-controlled. This is the highest tier of clinical evidence short of a completed regulatory review.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Retatrutide is not FDA-approved and is only available through clinical trials. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Oria BioStack provides evidence-based educational content about peptide science—we do not sell, prescribe, or recommend specific compounds.